View live charts, options flow & technicals for Edwards Lifesciences Corporation →
Open Dashboard
Edwards Lifesciences Corporation (EW) is a healthcare company in the medical devices industry with $6.51B in trailing revenue trading at a 51.4× trailing P/E — analyst consensus: buy.
Edwards Lifesciences Corporation provides products and technologies to treat advanced cardiovascular diseases in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL and EVOQUE brands. The company also provides surgical structural heart solutions, such as aortic surgical valve under the INSPIRIS brand name; INSPIRIS RESILIA aortic valve, which offers RESILIA tissue and VFit technology; KONECT RESILIA, a pre-assembled tissue valve conduit for complex combined procedures; and MITRIS RESILIA valve. It distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.
Key Statistics
Market Cap
$50.04B
Revenue (TTM)
$6.51B
EPS (TTM)
$1.69
EPS (Fwd est.)
$3.38
Employees
16,000
Trailing P/E
51.37
Forward P/E
25.71
PEG Ratio
1.89
Price / Sales
7.68
Price / Book
4.71
EV / EBITDA
23.34
Beta (5Y)
0.85
Analyst Consensus
Consensus
Buy
Analyst Price Target
+16.3% upside
Target: $100.96
Annual Revenue & Net Income
RevenueNet Income
'22
$4.46B
$1.52B
'23
$5.01B
$1.40B
'24
$5.44B
$4.17B
'25
$6.07B
$1.07B
Earnings History
Quarter
Actual EPS
Estimate
Result
Jul 2026
$0.78
$0.74
Beat (+5.1%)
Apr 2026
$0.78
$0.73
Beat (+7.3%)
Feb 2026
$0.58
$0.62
Miss (-6.3%)
Oct 2025
$0.67
$0.59
Beat (+12.6%)
Next Earnings Report
Edwards Lifesciences Corporation is next expected to report earnings on 29 Oct 2026.
What does Edwards Lifesciences Corporation (EW) do?
Edwards Lifesciences Corporation provides products and technologies to treat advanced cardiovascular diseases in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to tr…
What is EW's market cap?
Edwards Lifesciences Corporation has a market capitalization of approximately $50.04B.
What is EW's P/E ratio?
Edwards Lifesciences Corporation trades at a trailing P/E ratio of 51.4x and a forward P/E of 25.7x, which is above the broad market average of ~25x.
How much revenue does EW generate?
Edwards Lifesciences Corporation generated $6.51B in trailing 12-month revenue.
What do analysts say about EW?
The analyst consensus rating for Edwards Lifesciences Corporation is buy, with a mean price target of $100.96. That implies +16.3% upside from the current price.
When does EW report earnings?
Edwards Lifesciences Corporation is next scheduled to report earnings on 29 Oct 2026.
Does EW pay a dividend?
Edwards Lifesciences Corporation does not currently pay a regular dividend.
View live charts, options flow, gamma exposure, earnings history, and technical analysis for Edwards Lifesciences Corporation on Apsis Markets.
